Modulation of potassium channels as a therapeutic approach

Current Pharmaceutical Design

Volumn 12, Issue 4, 2006, Pages 459-470

  Lawson, K ^a   McKay, N G ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Cardiac delayed rectifier; Channelopathies; KCa; K+ channels; KCNQ; Kv1.3; Modulators; Therapeutic targets

Indexed keywords

1,3 DIHYDRO 5 (2 FLUOROPHENYL) 3 (1H INDOL 3 YLMETHYL) 1 METHYL 2H 1,4 BENZODIAZEPIN 2 ONE; 10,10 BIS(2 FLUORO 4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; ALMOKALANT; AZIMILIDE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CHROMANOL 293B; DOFETILIDE; FENAMIC ACID DERIVATIVE; FLECAINIDE; FLUPIRTINE; L 735821; LINOPIRDINE; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; PAXILLINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL STIMULATING AGENT; RESVERATROL; RETIGABINE; RILUZOLE; S 0100176; STILBENE DERIVATIVE; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; CELL FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG SELECTIVITY; DRUG TARGETING; EPILEPSY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPERPOLARIZATION; HYPOTENSION; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPOTENSION; REGULATORY MECHANISM; REPOLARIZATION; REVIEW; STROKE; ANIMAL; BIOLOGICAL MODEL; CLASSIFICATION; DRUG POTENTIATION; PHYSIOLOGY;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 33644916404     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474477     Document Type: Review

References (155)

1. Jan LY, Jan YN. Cloned potassium channels from eukaryotes and prokaryotes. Ann Rev Neurosci 1997; 20: 91-123.
2. Jan YL. Studies of voltage-dependent and inwardly rectifying potassium channels. Curr Top Membr 1999; 46: 1-5.
3. + channels. Ann N Y Acad Sci 1999; 868: 233-85.
4. + channels as therapeutic drug targets. Pharmacol Ther 2002; 94: 157-82.
5. Curran ME. Potassium ion channels and human disease: phenotypes to drug targets? Curr Opin Biotechnol 1998; 9: 565-72.
6. Cooper EC, Jan LY. Ion channel genes and human neurological disease: recent progress, prospects, and challenges. Proc Natl Acad Sci USA 1999; 96: 4759-66.
7. Felix R. Channelopathies: ion channel defects linked to heritable clinical disorders. J Med Genet 2000; 37: 729-40.
8. http://k-channels.med.nyu.edu/. Last visited 11 March 2004.
9. Yost CS. Potassium channels: basic aspects, functional roles, and medical significance. Anesthesiology 1999; 90: 1186-203.
10. Kaczorowski GJ, Knaus HG, Leonard RJ, McManus OB, Garcia ML. High-conductance calcium-activated potassium channels; structure, pharmacology, and function. J Bioenerg Biomembr 1996; 28: 255-67.
11. ATP channels. Physiol Rev 1998; 78: 227-45.
12. Trimmer JS. Regulation of ion channel expression by cytoplasmic subunits. Curr Opin Neurobiol 1998; 8: 370-4.
13. + channel beta subunits. Ann N Y Acad Sci 1999; 868: 344-55.
14. Lawson K. Potassium channel openers as potential therapeutic weapons in ion channel disease. Kidney Int 2000; 57: 838-45.
15. Coghlan MJ, Carroll WA, Gopalakrishnan M. Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J Med Chem 2001; 44: 1627-53.
16. + channel of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets 2001; 2: 401-22.
17. + channels: function, pharmacology and drugs. Curr Med Chem 2002; 9: 1385-95.
18. Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 2003; 6: 640-7.
19. Rees S, Curtis MJ. Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther 1996; 69: 199-217.
20. Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol 2000; 15: 41-53.
21. Tanaka T, Nagai R, Tomoike H, Takata S, Yano K, Yabuta K, et al. Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome. Circulation 1997; 95: 565-7.
22. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular-basis for cardiac-arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803.
23. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ, Baskin EP, Lynch JJ, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995; 26: 259-71.
24. Yao JA, Tseng GN. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol 1997; 8: 184-98.
25. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999; 10: 272-82.
26. + current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 1998; 38: 441-50.
27. Sun ZQ, Thomas GP, Antzelevitch C. Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J Cardiovasc Electrophysiol 2001; 12: 472-8.
28. Nakashima H, Gerlach U, Schmidt D, Nattel S. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res 2004; 61: 705-14.
29. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, Van-Raay TJ, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12: 17-23.
30. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96: 2778-81.
31. Saarinen K, Swan H, Kainulainen K, Toivonen L, Viitasalo M, Kontula K. Molecular genetics of the long QT syndrome: two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred. Hum Mutat 1998; 11: 158-65.
32. Li H, Chen Q, Moss AJ, Robinson J, Goytia V, Perry JC, et al. New mutations in the KVLQT1 potassium channel that cause long-QT syndrome. Circulation 1998; 97: 1264-9.
33. + channel gene and identification of C-terminal mutations in the long-QT syndrome. Circ Res 1999; 8: 20-7.
34. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997; 17: 338-40.
35. Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long-QT syndrome. Circulation 1998; 97: 142-6.
36. Abitbol I, Peretz A, Lerche C, Busch AE, Attali B. Stilbenes and fenamates rescue the loss of IKs channel function induced by an LQT5 mutation and other IsK mutants. EMBO J 1999; 18: 4137-48.
37. Zhou Z, Gong Q, January CT. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem 1999; 274: 31123-6.
38. + channel blocker AVE0118 in anesthetized pigs. Cardiovasc Res 2003; 60: 298-306.
39. + channels. J Biol Chem 2004; 279: 394-400.
40. Varro A, Biliczki P, Iost N, Virag L, Hala O, Kovaca P, et al. Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem 2004; 11: 1-11.
41. Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 2003; 7: 737-48.
42. Ronen GM, Rosales TO, Connolly M, Anderson VE, Leppert M. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology 1993; 43: 1355-60.
43. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998; 279: 403-6.
44. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998; 282: 1890-3.
45. Chorvat RJ, Zaczek R, Brown BS. Ion channel modulators that enhance acetylcholine release: potential therapies for Alzheimer's disease. Expert Opin Invest Drugs 1998; 7: 499-518.
46. Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Pryse-Phillips W, et al. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci 1997; 24: 140-5.
47. Borjesson A, Karlsson T, Adolfsson F, Ronnlund M, Nilsson L. Linopirdine (DUP 996): cholinergic treatment of older adults using successive and non-successive tests. Neuropsychobiol 1999; 40: 78-85.
48. Wang HS, Brown BS, McKinnon D, Cohen IS. Molecular basis for differential sensitivity of KCNQ and IKS channels to the cognitive enhancer XE991. Mol Pharmacol 2000; 57: 1218-23.
49. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, et at. Two new potent neurotransmitter release enhancers, 10, 10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10, 10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther 1998; 285: 724-30.
50. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000; 282: 73-6.
51. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000; 58: 591-600.
52. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001; 21: 5535-45.
53. www.xcelpharmaceuticals.com. Last visited 11 March 2004.
54. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993; 45: 548-69.
55. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 2003; 23: 7227-36.
56. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003; 460: 109-16.
57. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 382-90.
58. Rivera-Arconada I, Martinez-Gomez J, Lopez-Garcia JA. M-current modulators alter rat spinal nociceptive transmission: an electrophysiological study in vitro. Neuropharmacology 2004; 46: 598-606.
59. Perovic S, Bohm M, Meesters E, Meinhardt A, Pergande G, Muller WE. Pharmacological intervention in age-associated brain disorders by flupirtine: Alzheimer's and prion diseases. Mech Ageing Dev 1998; 101: 1-19.
60. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004; 62: 714-8.
61. Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain. A multivariate analysis. Arzneimittel-forschung 2003; 53: 496-502.
62. Jensen BS. BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev 2002; 8: 353-60.
63. Schroder RL, Jespersen T, Christ-ophersen P, Strobaek D, Jensen BS, Olesen SP. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001; 40: 888-98.
64. Dupuis DS, Schroder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, et al. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol 2002; 437: 129-37.
65. Gribkoff VK, Starrett JE Jr, Dworetzky SI. Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist 2001; 7: 166-77.
66. + channels: physiological role and pharmacology. Curr Med Chem 2003; 10: 649-61.
67. Lawson K. Is there a role for potassium channel openers in neuronal ion channel disorders? Expert Opin Invest Drugs 2000; 9: 2269-80.
68. Lawson K, Dunne MJ. Peripheral channelopathies as targets for potassium channel openers. Expert Opin Invest Drugs 2001; 10: 1345-59.
69. Cheney JA, Weisser JD, Bareyre FM, Laurer HL, Saatman KE, Raghupathi R, et al. The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 2001; 21: 396-403.
70. Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 2001; 7: 471-7.
71. Curran ME. Potassium ion channels and human disease: phenotypes to drug targets? Curr Opin Biotechnol 1998; 9: 565-72.
72. Kim KY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, et al. Cilostazol enhances casein kinase 2 phosphorylation and suppresses tumour necrosis factor-alpha-induced increased phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and apoptotic cell death in SK-N-SH cells. J Pharmacol Exp Ther 2004; 308: 97-104.
73. Hewawasam P, Fan W, Ding M, Flint K, Cook D, Goggins GD, et al. 4-Aryl-3-(hydroxyalkyl)quinolin-2-ones: novel maxi-K channel opening relaxants of corporal smooth muscle targeted for erectile dysfunction. J Med Chem 2003; 46: 2819-22.
74. 2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 2000; 48: 304-12.
75. +-deficient rats. FASEB J 2004; 18: 760-1.
76. Granados-Soto V, Arguelles CF, Ortiz MI. The peripheral antinociceptive effect of resveratrol is associated with activation of potassium channels. Neuropharmacology 2002; 43: 917-23.
77. Kraft R, Krause P, Jung S, Basrai D, Liebmann L, Bolz J, et al. BK channel openers inhibit migration of human glioma cells. Pflugers Archiv Eur J Physiol 2003; 446: 248-55.
78. + channel of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets 2001; 2: 401-22.
79. + channel, IKCal: a potential immunosuppressant. Proc Natl Acad Sci USA 2000; 97: 8151-6.
80. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003; 101: 2412-8.
81. Chilman-Blair K, Castaner J, Leeson PA. ICA-17043. Treatment of sickle cell disease gardos channel inhibitor. Drugs Future 2003; 28: 854-8.
82. + conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J Clin Invest 1997; 100: 3111-20.
83. + channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 2004; 65: 630-8.
84. + channel. Am J Physiol 1996; 271: L775-84.
85. - secretion by chlorzoxazone. J Pharmacol Exp Ther 2000; 292: 778-87.
86. Singh S, Syme CA, Singh AK, Devor DC, Bridges RJ. Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2001; 296: 600-11.
87. + channel modulators on human prostate cancer cell proliferation. Eur J Pharmacol 2003; 471: 157-64.
88. + channels in breast cancer cells: association with cell cycle progression. Am J Physiol Cell Physiol 2004; 287: C125-34.
89. Kohler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003; 108: 1119-25.
90. + channel. J Med Chem 2000; 43: 3478-81.
91. + channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther 2001; 296: 683-9.
92. + channels. Am J Physiol Cell Physiol 2000; 278: C570-81.
93. + channels. J Biol Chem 2001; 276: 9762-9.
94. Wolfart J, Neuhoff H, Franz O, Roeper J. Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J Neurosci 2001, 21: 3443-56.
95. Grunnet M, Jespersen T, Angelo K, Frokjaer-Jensen C, Klaerke DA, Olesen SP, et al. Pharmacological modulation of SK3 channels. Neuropharmacology 2001; 40: 879-87.
96. http://www.neurosearch.dk/index2.php. Last visited 11 March 2004.
97. Gargus JJ, Fantino E, Gutman GA. A piece in the puzzle: an ion channel candidate gene for schizophrenia. Mol Med Today 1998; 4: 518-24.
98. Tomita H, Shakkottai VG, Gutman GA, Sun G, Bunney WE, Cahalan MD, et al. Novel truncated isoform of SK3 potassium channel is a potent dominant-negative regulator of SK currents: implications in schizo-phrenia. Mol Psychiatry 2003; 8: 524-35.
99. + channels in human T lymphocytes. Mol Pharmacol 1995; 48: 98-104.
100. Nguyen A, Kath JC, Hanson DC, Biggers MS, Canniff PC, Donovan CB, et al. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation. Mol Pharmacol 1996; 50: 1672-9.
101. Hanson DC, Nguyen A, Mather RJ, Rauer H, Koch K, Burgess LE, et al. UK-78, 282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br J Pharmacol 1999; 126: 1707-16.
102. + channels: synthesis and photo-reactivity. J Med Chem 1998; 41: 4542-9.
103. Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, et al. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 2004; 101: 3112-7.
104. Pal S, Hartnett KA, Nerbonne JM, Levitan ES, Aizenman E. Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels. J Neurosci 2003; 23: 4798-802.
105. + channel inhibitor identified by high-throughput screening in yeast. Mol Pharmacol 2004; 65: 214-9.
106. Talley EM, Bayliss DA. Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action. J Biol Chem 2002; 277: 17733-42.
107. Danthi S, Enyeart JA, Enyeart JJ. Caffeic acid esters activate TREK-1 potassium channels and inhibit depolarization-dependent secretion. Mol Pharmacol 2004; 65: 599-610.
108. + channels. Nat Neurosci 1999; 2: 422-6.
109. + channels TREK-1 and TRAAK. Brain Res 2001; 892: 94-101.
110. + channels TREK-1 and TRAAK. Mol Pharmacol 2000; 57: 906-12.
111. Mitcheson JS, Sanguinetti MC. Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels. Cell Physiol Biochem 1999; 9: 201-16.
112. Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004; 62: 9-33.
113. +, transient outward, and delayed rectifier currents in canine atrial myocytes. Circ Res 1998; 83: 158-66.
114. Marban E. Cardiac channelopathies. Nature 2002; 415: 213-8.
115. Wu YJ, Boissard CG, Greco C, Gribkoff VK, Harden DG, He H, et al. (S)-N-[1-(3-morpholin-4-yl-phenyl)ethyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J Med Chem 2003; 46: 3197-200.
116. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A, et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol 1997; 158: 5120-8.
117. + channels improves experimental autoimmune encephalo-myelitis and inhibits T cell activation. J Immunol 2001; 166: 936-44.
118. Price M, Lee SC, Deutsch C. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1989; 86: 10171-5.
119. + channel openers. Bioorg Med Chem Lett 2003; 13: 3971-4.
120. + channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles. Bioorg Med Chem Lett 2003; 13: 2003-7.
121. + channel isoforms from human brain. Neuron 1994; 13: 1315-30.
122. Lagrutta A, Shen KZ, North RA, Adelman JP. Functional differences among alternatively spliced variants of Slowpoke, a Drosophila calcium-activated potassium channel. J Biol Chem 1994; 269: 20347-51.
123. McManus OB, Helms LM, Pallanck L, Ganetzky B, Swanson R, Leonard RJ. Functional role of the beta subunit of high conductance calcium-activated potassium channels. Neuron 1995; 14: 645-50.
124. Dworetzky SI, Boissard CG, Lum-Ragan JT, McKay MC, Post-Munson DJ, Trojnacki JT, et al. Phenotypic alteration of a human BK (hSlo) channel by hSlobeta subunit coexpression: changes in blocker sensitivity, activation/relaxation and inactivation kinetics, and protein kinase A modulation. J Neurosci 1996; 16: 4543-50.
125. Xie J, McCobb DP. Control of alternative splicing of potassium channels by stress hormones. Science 1998; 280: 443-6.
126. + channels: a transmembrane beta-subunit homolog. Proc Natl Acad Sci USA 1999; 96: 4137-42.
127. Brenner R, Jegla TJ, Wickenden A, Liu Y, Aldrich RW. Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4. J Biol Chem 2000; 275: 6453-61.
128. Ca channels formed by bis-cistronic expression of hSlo α and β1-4 subunits in HEK293 cells. J Membrane Biol 2003; 192: 141-8.
129. Shipston MJ. Alternative splicing of potassium channels; a dynamic switch of cellular excitability. Trends Cell Biol 2001; 11: 353-8.
130. Kalman K, Pennington MW, Lanigan MD, Nguyen A, Rauer H, Mahnir V, et al. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 1998; 273: 32697-707.
131. + channels ameliorates experimental autoimmune encephalo-myelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 2001; 98: 13942-7.
132. Wanner SG, Glossmann H, Knaus HG, Baker R, Parsons W, Rupprecht KM, et al. WIN 17317-3, a new high-affinity probe for voltage-gated sodium channels. Biochemistry 1999; 38: 11137-46.
133. Vianna-Jorge R, Oliveira CF, Garcia ML, Kaczorowski GJ, Suarez-Kurtz G. Correolide, a nor-triterpenoid blocker of Shaker-type Kv1 channels elicits twitches in guinea-pig ileum by stimulating the enteric nervous system and enhancing neurotransmitter release. Br J Pharmacol 2000; 131: 772-8.
134. Chandy KG, Gutman GA. Voltage-gated potassium channel genes. In: Handbook of Receptors and Channels. CRC Press, Boca Raton, FL, USA 1995; 1-71.
135. Lew A, Chamberlin AR. Human T-cell Kv1.3 potassium channel blockers: new strategies for immunosuppression. Exp Opin Therap Pat 2000; 10: 905-15.
136. + channel revealed by the NMR-derived structures of scorpion toxins. Neuron 1995; 15: 1169-81.
137. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 1997; 94: 11651-6.
138. Logsdon NJ, Kang J, Togo JA, Christian EP, Aiyar J. A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J Biol Chem 1997; 272: 32723-6.
139. + channel. Am J Physiol 1998; 275: C848-56.
140. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, et al. Up-regulation of the IKCal potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000; 275: 37137-49.
141. + channels in human B lymphocytes and rat thymocytes. J Physiol 1989; 415: 69-83.
142. Partiseti M, Choquet D, Diu A, Korn H. Differential regulation of voltage- and calcium-activated potassium channels in human B lymphocytes. J Immunol 1992; 148: 3361-8.
143. Grissmer S, Nguyen AN, Cahalan MD. Calcium-activated potassium channels in resting and activated human T lymphocytes. Expression levels, calcium dependence, ion selectivity, and pharmacology. J Gen Physiol 1993; 102: 601-30.
144. + channels. Proc Natl Acad Sci USA 1999; 96: 10917-21.
145. 2+ clearance distinguish Th1 and Th2 lympho-cytes. J Immunol 2000; 164: 1153-60.
146. Ca channel blockers. Bioorg Med Chem Lett 2003; 13: 2637-9.
147. Rane SG. Potassium channels as targets for modulating cell growth and differentiation. Perspect Drug Discov 1999; 16: 295-311.
148. Ca channel diversity and smooth muscle cell function. Circ Res 1999; 85: E33-43.
149. Melman A, Zhao W, Davies KP, Bakal R, Christ GJ. The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol 2003; 170: 285-90.
150. Christ GJ, Day NS, Day M, Santizo C, Zhao W, Sclafani T, et al. Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1699-709.
151. Mazhari R, Nuss HB, Armoundas AA, Winslow RL, Marban E. Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval. J Clin Invest 2002; 109: 1083-90.
152. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003; 107: 2037-44.
153. Huang X, Liu H, Cui M, Fu W, Yu K, Chen K, et al. Simulating the interactions of toxins with K+ channels. Curr Pharm Design 2004; 10(9): 1057-67.
154. Rodrigo GC, Standen NB. ATP-sensitive potassium channels. Curr Pharm Design 2005; 11(15): 1915-40.
155. Wassermann GF, Loss ES. Testosterone action on the Sertoli cell membrane: a KIR6.x channel related effect. Curr Pharm Design 2004; 10(21): 2649-56.